[ad_1] RT @ModernRetina: The U.S. Centers for Medicare and Medicaid Services code is effective July 1 and will enhance access to Xipere, the only… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Looking forward to discussing drug delivery and durability at OIS ASRS! https://t.co/hOsw51ABAd [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @OphthTimes: @BauschLomb annonced today it has received a permanent J-Code for triamcinolone acetonide injectable suspension (Xipere). #… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Just published: https://t.co/iavHrQFgR9 “Longer-Term Anti-VEGF Therapy Outcomes in Neovascular #AMD, #DME, and RVO Macu… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Integrated analysis of two clinical trials | IOVS | ARVO Journals https://t.co/bMb8UImn5o [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Targeting, Compartmentalization and Durability of Suprachoroidally Injected Small Molecule Suspensions in Multiple Preclinical Models | IOVS | ARVO Journals https://t.co/b1Rof8D9aD [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Honored to present at the Macula Society Annual Meeting today! #eyes #retina #macula #maculardegeneration #AMD #ophthalmology #clinicalresearch https://t.co/mrUMR1zRsG [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.